GlaxoSmithKline: head-to-head against Merck
Pharmaceutical Business Review - Vaccines against HPV, potentially protecting against cervical cancer, are forecast to become multi-billion dollar products. Since Merck's Gardasil has already been launched, GSK has taken the unusual step of undertaking a phase III study that
Source: www.pharmaceutical-business-review.com
Click here for more information about depression forum depression forum
<< Home